期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到840篇文章
< 1 2 … 42 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial 认领 引用 被引量：18
1
作者 Jin-ji Yang Qing Zhou +6 位作者 Ri-qiang Liao Yi-sheng Huang Chong-rui Xu Zhen Wang Bin-chao Wang Hua-jun Chen Yi-long Wu 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2012年第2期97-102,共6页
Objective： To evaluate the efficacy and safety of nedaplatin/gemcitabine （NG） and carboplatin/gemcitabine （CG） in the management of untreated advanced non-small cell lung cancer （NSCLC）. Methods： Sixty-two pat... Objective： To evaluate the efficacy and safety of nedaplatin/gemcitabine （NG） and carboplatin/gemcitabine （CG） in the management of untreated advanced non-small cell lung cancer （NSCLC）. Methods： Sixty-two patients with previously untreated advanced NSCLC were recruited between June 2006 and November 2007. Subjects were randomly assigned to the NG arm （n=30） and the CG arm （n=32）. Only patients （24 and 25 in the NG and CG arms, respectively） who completed 〉2 chemotherapy cycles were included in the data analysis. The primary outcome measure was the objective response rate （ORR）. The secondary outcome measures included progression-free survival （PFS）, overall survival （OS） and adverse events. Results： There were no statistically significant differences in the efficacy measures （ORR, P=0.305; median PFS, P=0.298, median OS, P=0.961） or in the major adverse events （grade 3/4 neutropenia, P=0.666; grade 3/4 anemia, P=0.263; grade 3/4 thrombocytopenia, P=0.222） between the two treatment arms. However, there was a trend towards higher ORR （37.5% vs. 24.0%）, longer PFS （6.0 vs. 5.0 months）, and less adverse events in the NG arm. Conclusion： NG regimen seems to be superior over CG regimen for advance NSCLS, but further investigation is needed to validate this superiority. 展开更多
关键词 Non-small cell lung cancer Chemotherapy Nedaplatin Carboplatin Gemcitabine Squamous cell carcinoma
暂未订购 下载PDF
Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma 认领 引用 被引量：25
2
作者 Ze-Tian Shen Xin-Hu Wu +4 位作者 Bing Li Jun-Shu Shen Zhen Wang Jing Li Xi-Xu Zhu 《World Journal of Gastroenterology》 SCIE CAS 2013年第48期9447-9452,共6页
AIM:To evaluate the efficacy and toxicity of nedaplatin(NDP)concurrent with radiotherapy in the treatment of locally advanced esophageal carcinoma.METHODS:Sixty-eight patients with locally advanced esophageal carcinom... AIM:To evaluate the efficacy and toxicity of nedaplatin(NDP)concurrent with radiotherapy in the treatment of locally advanced esophageal carcinoma.METHODS:Sixty-eight patients with locally advanced esophageal carcinoma were randomized into either a NDP group(n=34)or a cisplatin(DDP)group(n=34).The NDP group received NDP 80-100 mg/m2iv on day 1+leucovorin(CF)100 mg/m2iv on days 1-5+5-fluorouracil(5-FU)500 mg/m2iv on days 1-5.The DDP group received DDP 30 mg/m2iv on days 1-3+CF 100 mg/m2on days 1-5+5-FU 500 mg/m2iv on days 1-5.The treatment was repeated every 4 wk in both groups.Concurrent radiotherapy[60-66 Gy/(30-33f)/(6-7 wk)]was given during chemotherapy.RESULTS:There was no significant difference in the short-term response rate between the NDP group and DDP group(90.9%vs 81.3%,P=0.528).Although the 1-and 2-year survival rates were higher in the NDP group than in the DDP group(75.8%vs 68.8%,57.6%vs 50.0%),the difference in the overall survival rate was not statistically significant between the two groups(P=0.540).The incidences of nausea,vomiting and nephrotoxicity were significantly lower in the NDP group than in the DDP group(17.6%vs 50.0%,P=0.031;11.8%vs 47.1%,P=0.016;8.8%vs 38.2%,P=0.039).There was no significant difference in the incidence of myelosuppression,radiation-induced esophagitis or radiation-induced pneumonia between the two groups.CONCLUSION:NDP-based concurrent chemoradiotherapy is effective and well-tolerated in patients with locally advanced esophageal carcinoma.NDP-based regimen has comparable efficacy to DDP-based regimen but is associated with lower incidences of gastrointestinal and renal toxicity. 展开更多
关键词 Esophageal carcinoma Chemoradiotherapy Nedaplatin Cisplatin
暂未订购 下载PDF
A phase Ⅱ study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma 认领 引用 被引量：16
3
作者 Yi-Fu He Chu-Shu Ji +7 位作者 Bing Hu Ping-Sheng Fan Chang-Lu Hu Feng-Shou Jiang Jian Chen Lei Zhu Yi-Wei Yao Wei Wang 《World Journal of Gastroenterology》 SCIE CAS 2013年第35期5910-5916,共7页
AIM:To evaluate the efficacy and safety of paclitaxelnedaplatin combination as a front-line regimen in Chinese patients with metastatic esophageal squamous cell carcinoma(ESCC).METHODS:A two-center,open-label,single-a... AIM:To evaluate the efficacy and safety of paclitaxelnedaplatin combination as a front-line regimen in Chinese patients with metastatic esophageal squamous cell carcinoma(ESCC).METHODS:A two-center,open-label,single-arm phaseⅡstudy was designed.Thirty-nine patients were enrolled and included in the intention-to-treat analysis of efficacy and adverse events.Patients received 175mg/m2of paclitaxel over a 3 h infusion on 1 d,followed by nedaplatin 80 mg/m2in a 1 h infusion on 2 d every3 wk until the documented disease progression,unac-ceptable toxicity or patient’s refusal.RESULTS:Of the 36 patients assessable for efficacy,there were 2 patients(5.1%)with complete response and 16 patients(41.0%)with partial response,giving an overall response rate of 46.1%.The median progression-free survival and median overall survival for all patients were 7.1 mo(95%CI:4.6-9.7)and 12.4 mo(95%CI:9.5-15.3),respectively.Toxicities were moderate and manageable.Grade 3/4 toxicities included neutropenia(15.4%),nausea(10.3%),anemia(7.7%),thrombocytopenia(5.1%),vomiting(5.1%)and neutropenia fever(2.6%).CONCLUSION:The combination of paclitaxel and nedaplatin is active and well tolerated as a first-line therapy for patients with metastatic ESCC. 展开更多
关键词 Esophageal squamous cell cancer Frontline chemotherapy Paclitaxel Nedaplatin
暂未订购 下载PDF
Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma 认领 引用 被引量：1
4
作者 Rui-Xue Huo Ying-Ying Jin +12 位作者 Yong-Xue Zhuo Xiao-Tong Ji Yu Cui Xiao-Jing Wu Yi-Jia Wang Long Zhang Wen-Hua Zhang Yu-Mei Cai Cheng-Cheng Zheng Rui-Xue Cui Qian-Ye Wang Zhen Sun Feng-Wei Wang 《World Journal of Clinical Cases》 SCIE 2022年第11期3414-3425,共12页
BACKGROUND Patients with recurrent or locally advanced head and neck squamous cell carcinoma(HNSCC)typically have limited treatment options and poor prognosis.AIM To evaluate the efficacy and safety of two drugs with ... BACKGROUND Patients with recurrent or locally advanced head and neck squamous cell carcinoma(HNSCC)typically have limited treatment options and poor prognosis.AIM To evaluate the efficacy and safety of two drugs with potent radio-sensitization properties including gemcitabine and nedaplatin as concurrent chemoradiotherapy regimens in treating HNSCC.METHODS This single-arm prospective study enrolled patients with HNSCC to receive gemcitabine on days 1 and 8 and nedaplatin on days 1 to 3 for 21 days.Intensitymodulated radiation therapy with a conventional fraction was delivered 5 days per week.Objective response rate(ORR),disease control rate,and toxicity were observed as primary endpoints.Overall survival(OS)and progression free survival were recorded and analyzed as secondary endpoints.RESULTS A total of 24 patients with HNSCC were enrolled.During the median 22.4-mo follow-up,both ORR and disease control rate were 100%.The one-year OS was 75%,and one-year progression-free survival(PFS)was 66.7%(median PFS was 15.1 mo).Recurrent HNSCC patients had a poorer prognosis than the treatment-naïve patients,and patients who achieved complete response had better survival than those in the PR group(all P<0.05).The most common grade 1-4(100%)or grade 3-4 toxicities(75%)were hematological,and the most common grade 3-4 non-hematological toxicity was mucositis in 17(71%)patients.CONCLUSION Gemcitabine plus nedaplatin with concurrent chemoradiotherapy is a therapeutic option for HNSCC with predictable tolerability.Considering the high adverse event rate,the optimized dose and schedule must be further explored. 展开更多
关键词 Chemoradiotherapy Gemcitabine Nedaplatin Head and neck cancer Recurrent Locally advanced
暂未订购 下载PDF
Clinical observation of nedaplatin concurrent with radiotherapy for mid-advanced nasopharyngeal carcinoma and esophageal carcinoma 认领 引用
5
作者 Fangfang Jie Wei Ge Pingping He Ling Zhang 《The Chinese-German Journal of Clinical Oncology》 2010年第11期652-655,共4页
Objective: The aim of our study was to evaluate the short-term efficacy and the toxic reaction of nedaplatin concurrent with radiotherapy for mid-advanced nasopharyngeal carcinoma and esophageal carcinoma. Methods: Th... Objective: The aim of our study was to evaluate the short-term efficacy and the toxic reaction of nedaplatin concurrent with radiotherapy for mid-advanced nasopharyngeal carcinoma and esophageal carcinoma. Methods: Thirty-four patients were confirmed diagnosis with cancer by pathologic results. All patients were given 6MV X-ray for radiotherapy, Dt 66-70 Gy/33-35 f/6-7 w, concurrently administrated nedaplatin (30 mg/m2) once a week (6 times). Results: A total 34 patients were enrolled, of whom 33 patients were available for objective response, 1 patient of esophageal cancer quit for allergic reaction. The response rate (RR) of nedaplatin-contained therapy for nasopharyngeal carcinoma and esophageal carcinoma were 90.0% and 76.9%, respectively. The major toxic reaction was bone marrow suppression observed in 25 patients (73.5%), in which grade III aleukocytosis was observed in 3 patients (8.8%), grade III + IV thrombocytopenia in 3 patients (8.8%). And 6 patients (17.6%) showed gastrointestinal tract reaction. There were 4 patients with radiation esophagitis in the 13 patients with esophageal carcinoma. Conclusion: Nedaplatin can increase the therapeutic effect of radiation. Its incidence rate of bone marrow suppression is high, but the gastrointestinal tract reaction and renal toxicity is low and mild. 展开更多
关键词 nedaplatin nasopharyngeal carcinoma esophageal carcinoma toxic reaction
暂未订购 下载PDF
17 cases of advanced non-small cell lung cancer treated with paclitaxel liposome plus nedaplatin 认领 引用 被引量：1
6
作者 Tao Suo Wei Ge +2 位作者 Jinzhong Zhang Yongfa Zheng Shunxiang Luo 《The Chinese-German Journal of Clinical Oncology》 2012年第4期196-198,共3页
Objective： The aim of this study was to evaluate the recent efficacy and adverse reactions of paclitaxel liposome plus nedaplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： Seventeen... Objective： The aim of this study was to evaluate the recent efficacy and adverse reactions of paclitaxel liposome plus nedaplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods： Seventeen cases of NSCLC treated with paclitaxel liposome and nedaplatin for 2 to 6 cycles, by infusing paclitaxel liposome 135 mg/m^2 for 3 h on d 1 and nedaplatin 80 mg/m^2 as infusion on d2. Results： Among 17 patients being evaluated for response to treatment, 1 achieved complete response （CR）, 4 achieved partial response （PR）, 3 achieved stable disease （SD）, 9 achieved progress disease （PD）. The main adverse reaction was haematological toxicities, especially leukopenia and thrombocytopenia. The non-hae- matological toxicities included nausea, vomiting, mild hepatic dysfunction, alopecia and so on. Conclusion： Paclitaxel lipo- some plus nedaplatin was effective and well tolerated for treating patients with advanced NSCLCo 展开更多
关键词 paclitaxel liposome nedaplatin non-small cell lung cancer （NSCLC）
暂未订购 下载PDF
Nedaplatin-induced syndrome of inappropriate secretion of antidiuretic hormone:A case report and review of the literature 认领 引用 被引量：1
7
作者 Lei Tian Li-Ya He Hong-Zhen Zhang 《World Journal of Clinical Cases》 SCIE 2021年第23期6810-6815,共6页
BACKGROUND Syndrome of inappropriate secretion of antidiuretic hormone(SIADH)is relatively common in several cancers,such as small cell lung cancer.However,nedaplatin-induced SIADH is rare.We describe a case of SIADH ... BACKGROUND Syndrome of inappropriate secretion of antidiuretic hormone(SIADH)is relatively common in several cancers,such as small cell lung cancer.However,nedaplatin-induced SIADH is rare.We describe a case of SIADH mediated by nedaplatin.CASE SUMMARY A 54-year-old female with nasopharyngeal carcinoma was treated with nedaplatin and developed severe hyponatremia due to SIADH.The side effects were successfully treated by fluid restriction and sodium supplementation.CONCLUSION This case report highlights the importance of cautiously treating life-threatening hyponatremia in patients treated with nedaplatin. 展开更多
关键词 Nedaplatin Syndrome of inappropriate secretion of antidiuretic hormone Hyponatremia Fluid restriction Sodium supplementation Case report
暂未订购 下载PDF
Short-term effects of nedaplatin plus futraful chemotherapy in treatment of advanced esophageal carcinoma 认领 引用 被引量：1
8
作者 Lianggeng Xiong Youshan Li 《The Chinese-German Journal of Clinical Oncology》 2009年第5期273-275,共3页
Objective:To observe the efficacy and the side effects of nedaplatin with futraful in the treatment of advanced esophageal carcinoma.Methods:Observing group NDP/FT-207 regimen:given nedaplatin 80-100 mg/m2 on day 1 an... Objective:To observe the efficacy and the side effects of nedaplatin with futraful in the treatment of advanced esophageal carcinoma.Methods:Observing group NDP/FT-207 regimen:given nedaplatin 80-100 mg/m2 on day 1 and futraful 500-600 mg/m2 on day 1 to 5;control group:DDP/5-Fu regimen received cisplatin 80-100 mg/m2 on day 1 and 5-Fluorouracil 500-750 mg/m2 on day 1 to 5.In both groups per 28 days was a cycle, 2-3 cycles were one course.Results:Response and toxicity could be assessed in all the 78 patients, 42 patients were in observing group, the other 36 patients were in control group.The response rate of patients treated by NDP/FT-207 and DDP/5-Fu were 57.1%(24/42) and 50%(18/36) respectively.The two groups have no significant difference.The toxicities as gastrointestinal disorders and myelosuppression in observing group was lighter than those in control group.Conclusion:The combination of NDP and FT-207 is a safer and effective regimen. 展开更多
关键词 esophageal carcinoma nedaplatin futraful
暂未订购 下载PDF
The early efficacy of the nedaplatin and megestrol combine chemoradiotherapy to the advanced cervical cancers 认领 引用
9
作者 Qinghua Ke Shiqiong Zhou Xiaoyan Su Zheng Liu Wentao Zhang Jiyuan Yang 《The Chinese-German Journal of Clinical Oncology》 2011年第8期480-483,共4页
Objective： The aim of this study was to investigate the early outcome of the nedaplatin and megestrol combine chemoradiotherapy to the advanced cervical cancer. Methods： Forty-two cases with cervical cancer （FIGO l... Objective： The aim of this study was to investigate the early outcome of the nedaplatin and megestrol combine chemoradiotherapy to the advanced cervical cancer. Methods： Forty-two cases with cervical cancer （FIGO lib to IVa） were divided randomly into two groups, radiotherapy alone （RT group： 21 cases） and radiation combines chemotherapy （nedaplatin and megestrol） （RT ＋ C group： 21 cases）. There was no difference of radiotherapy between the two groups, the RT ＋ C group accepted nedaplatin injection during the radiation weekly, according to 30 mg/m^2 ,these regimen were given for 4-5 weeks. This group was received an oral medicine megestro1160 mg every day during the treatment. Results： The RT ＋ C group： the complete remission rate was 80.9% （17/21）, the partial remission rate was 19.1% （4/21）, the effective rate was 100%. The RT group： the complete remission rate was 38.1% （8/21） and partial remission rate was 32.9% （9/21）, the effective rate was 81.0%. The total effective rate and complete remission rate of RT ＋ C group were higher than RT group. There was significant difference between the two groups. The 1-year survival rates respectively were 100% （21/21） in RT ＋ C group, 80.9% （17/21） in RT group. There was statistically significant difference between the two groups （x^2 = 4.42 〉 3.84, P 〈 0.05）. Conclusion： The nedaplatin and megestrol combine chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and the adverse effects was raised, but that can be endured. 展开更多
关键词 cervical nedaplatin chemoradiotherapy
暂未订购 下载PDF
Effect of Endo Combined with Paclitaxel and Nedaplatin Concurrent Chemotherapy and Radiotherapy on Quality of Life of Patients with Non-small Cell Lung Cancer 认领 引用
10
作者 ZHANShucai WANGXianyong 《外文科技期刊数据库（文摘版）医药卫生》 2022年第8期132-136,共5页
Objective: to explore the effect of Endo combined with paclitaxel and nedaplatin on the quality of life of patients with non-small cell lung cancer. Methods: from January 2019 to December 2021, 32 patients with non-sm... Objective: to explore the effect of Endo combined with paclitaxel and nedaplatin on the quality of life of patients with non-small cell lung cancer. Methods: from January 2019 to December 2021, 32 patients with non-small cell lung cancer in our hospital were randomly divided into two groups, with 16 cases in each group. Paclitaxel, nedaplatin combined with Endor were used to compare the curative effects. Results: there was no significant difference in quality of life between the two groups before treatment (P＞0.05). Compared with the control group, the observation group had lower quality of life score and higher curative effect (P＜0.05). Conclusion: endorsement combined with chemotherapy is effective in the treatment of non-small cell lung cancer, which can significantly improve the chemotherapy effect and quality of life of patients. 展开更多
关键词 endo paclitaxel nedaplatin non-small cell lung cancer quality of life
暂未订购 下载PDF
Study on Clinical Effect of Nedaplatin Chemotherapy Combined with Radiotherapy in Patients with Cervical Cancer and Its Influence on Survival Time 认领 引用
11
作者 LYU Shuang 《外文科技期刊数据库（文摘版）医药卫生》 2021年第11期469-471,共3页
Objective: to analyze the clinical value of nedaplatin in chemotherapy and radiotherapy for cervical cancer. Methods: 96 cases of cervical cancer in our hospital were selected in a randomized double-blind way. The tre... Objective: to analyze the clinical value of nedaplatin in chemotherapy and radiotherapy for cervical cancer. Methods: 96 cases of cervical cancer in our hospital were selected in a randomized double-blind way. The treatment period was from January 2020 to March 2021, including the study group (n = 48 cases) and the control group (n = 48 cases). For the clinical treatment, the control group was treated by cisplatin chemotherapy, while the research group was treated by nedaplatin chemotherapy and radiotherapy. The therapeutic effect and survival time between the two groups were comprehensively compared. Results: after carrying out chemotherapy and radiotherapy, the effective rate of treatment was significantly higher in the study group. For the long-term survival period, the study group is more superior, and there is a significant difference in P value among the groups. Conclusion: in view of cervical cancer cases, nedaplatin is adopted in the process of chemotherapy and radiotherapy, which can greatly promote the improvement of patients' quality of life and can significantly improve the long-term survival. It should be vigorously promoted in clinical practice. 展开更多
关键词 cervical cancer nedaplatin chemotherapy and radiotherapy survival time
暂未订购 下载PDF
信迪利单抗联合白蛋白结合型紫杉醇、奈达铂一线治疗食管癌的临床研究 认领 引用 被引量：1
12
作者 韩冬 于韬 +3 位作者 严文俊 潘家俊 李宇峰 薛东明 《中国现代医学杂志》 CAS 2026年第6期48-53,共6页
目的探讨信迪利单抗联合白蛋白结合型紫杉醇、奈达铂一线治疗食管癌的临床疗效、安全性及免疫学指标变化。方法选取2020年5月—2023年12月徐州市第一人民医院收治的100例食管癌患者,随机分为观察组和对照组,各50例。对照组采用白蛋白结... 目的探讨信迪利单抗联合白蛋白结合型紫杉醇、奈达铂一线治疗食管癌的临床疗效、安全性及免疫学指标变化。方法选取2020年5月—2023年12月徐州市第一人民医院收治的100例食管癌患者,随机分为观察组和对照组,各50例。对照组采用白蛋白结合型紫杉醇与奈达铂治疗,观察组对照组基础上加用信迪利单抗治疗。于治疗前后对两组患者进行疗效评估,并检测肿瘤标志物[细胞角蛋白19片段抗原21-1(CYFRA21-1)、鳞状细胞癌抗原(SCC-Ag)、癌胚抗原(CEA)]、免疫功能指标(CD3+、CD4+、CD8+、CD4+/CD8+)、血清程序性死亡受体1(PD-1)、程序性死亡配体1(PD-L1)水平及不良反应发生情况。结果观察组疾病控制率更高(P0.05)。结论信迪利单抗联合白蛋白结合型紫杉醇、奈达铂对食管癌具有较好的疗效,能够改善免疫功能,降低肿瘤标志物水平,且不良反应可耐受,值得在临床上推广应用。 展开更多
关键词 食管癌 信迪利单抗 白蛋白结合型紫杉醇 奈达铂 免疫功能 肿瘤标志物
暂未订购 下载PDF
恩沃利单抗联合紫杉醇奈达铂序贯放化疗对晚期宫颈癌的疗效 认领 引用
13
作者 马韬 张妙琴 李伟华 《中国药物应用与监测》 CAS 2026年第5期691-695,共5页
目的探讨恩沃利单抗联合紫杉醇和奈达铂序贯同步放化疗治疗晚期宫颈癌的临床疗效及安全性。方法采用前瞻性随机对照研究方法,选取2023年6月至2024年6月山西医科大学附属运城市中心医院予以针对性治疗的134例晚期宫颈癌患者为研究对象,... 目的探讨恩沃利单抗联合紫杉醇和奈达铂序贯同步放化疗治疗晚期宫颈癌的临床疗效及安全性。方法采用前瞻性随机对照研究方法,选取2023年6月至2024年6月山西医科大学附属运城市中心医院予以针对性治疗的134例晚期宫颈癌患者为研究对象,用随机数字表法将其分为对照组(67例,给予紫杉醇和奈达铂序贯同步放化疗)和观察组(67例,给予恩沃利单抗联合紫杉醇和奈达铂序贯同步放化疗)。比较两组近期疗效、肿瘤标志物水平、免疫功能指标、不良反应发生率及无进展生存期。结果观察组的客观缓解率、疾病控制率均高于对照组[85.07%(57/67)vs 67.16%(45/67),95.52%(64/67)vs 85.07%(57/67),χ2=5.912、4.174,均P0.05)。观察组中位无进展生存期长于对照组(13.2 vs 9.1个月,log-rank检验,χ2=4.936,P<0.05)。结论恩沃利单抗联合紫杉醇奈达铂序贯同步放化疗治疗晚期宫颈癌,可提高近期疗效、保护免疫功能并延长无进展生存期,且安全性良好。 展开更多
关键词 晚期宫颈癌 恩沃利单抗 紫杉醇 奈达铂 同步放化疗 肿瘤标志物 免疫功能
暂未订购 下载PDF
奈达铂化疗联合逆行调强放疗治疗晚期宫颈癌的疗效评价及对血清趋化素脂肪因子与HMGB1表达的影响 认领 引用
14
作者 苏敏 蒋利华 +6 位作者 冯萍 曹炯睿 杨巾 刘丽 胡书源 高云 沈立 《黑龙江医学》 2026年第13期1567-1570,1574,共4页
目的:评价奈达铂化疗联合逆行调强放疗治疗晚期宫颈癌的疗效,并观察其对血清趋化素脂肪因子与血清高迁移率族蛋白B1(HMGB1)表达的影响。方法:选取2022年1月—2024年1月样本医院收治的96例晚期宫颈癌患者作为研究对象,随机将其分为3组,... 目的:评价奈达铂化疗联合逆行调强放疗治疗晚期宫颈癌的疗效,并观察其对血清趋化素脂肪因子与血清高迁移率族蛋白B1(HMGB1)表达的影响。方法:选取2022年1月—2024年1月样本医院收治的96例晚期宫颈癌患者作为研究对象,随机将其分为3组,每组各32例。对照组患者单纯使用放疗技术,观察1组患者采用洛铂联合逆向调强放疗治疗,观察2组患者采用奈达铂联合逆向调强放疗治疗。比较3组患者疗效、安全性及治疗前后肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)]、脂肪因子[脂联素(APN)、趋化素(chemerin)、丝氨酸蛋白酶抑制剂(vaspin)]、免疫调控因子的表达水平及1年生存率变化。结果:治疗后,观察1组、观察2组患者总有效率及疾病控制率均高于对照组患者,但观察1组、观察2组相比,差异无统计学意义(P>0.05);观察1组、观察2组患者APN均高于对照组患者,chemerin、vaspin表达均低于对照组,其中观察2组更低,差异均有统计学意义(P<0.05);观察1组、观察2组患者CEA、CA125和CA153水平均低于对照组,其中观察2组更低,差异均有统计学意义(P<0.05);观察2组患者CD8+T细胞浸润增加明显大于其他两组,Tregs比例下降大于其他两组,差异均有统计学意义(P<0.05);观察2组患者毒副反应总发生率最低,且观察2组患者体质量下降幅度少于其他两组,差异均有统计学意义(P<0.05);观察2组患者半年及1年的生存率最高,差异均有统计学意义(P<0.05)。结论:奈达铂化疗联合逆行调强放疗治疗晚期宫颈癌疗效明显的同时,能更好地改善患者血清中肿瘤标志物水平,并调节趋化素脂肪因子和HMGB1表达,且患者耐受性较好,有着较高的安全性。 展开更多
关键词 奈达铂化疗 逆行调强放疗 晚期宫颈癌 血清趋化素脂肪因子 HMGB1表达的影响
暂未订购 下载PDF
调强放疗联合奈达铂同步化疗对局部晚期头颈部鳞状细胞癌患者的疗效分析 认领 引用
15
作者 彭丹丹 刘永志 《实用癌症杂志》 2026年第2期223-226,共4页
目的探讨调强放疗联合奈达铂同步化疗对局部晚期头颈部鳞状细胞癌(HNSCC)患者的疗效。方法采用随机数字表法将116例局部晚期HNSCC患者分为两组。对照组(n=58例)采用调强放疗联合5氟尿嘧啶同步化疗,观察组(n=58例)采用调强放疗联合奈达... 目的探讨调强放疗联合奈达铂同步化疗对局部晚期头颈部鳞状细胞癌(HNSCC)患者的疗效。方法采用随机数字表法将116例局部晚期HNSCC患者分为两组。对照组(n=58例)采用调强放疗联合5氟尿嘧啶同步化疗,观察组(n=58例)采用调强放疗联合奈达铂同步化疗。对比两组临床疗效、肿瘤标志物水平、免疫功能、生存质量、不良反应。结果观察组临床总有效率[84.48%(49/58)]高于对照组[62.07%(36/58)],差异有统计学意义(χ2=7.440,P=0.006);观察组治疗后鳞状细胞癌相关抗原(SCC-Ag)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、胸苷激酶1(TK1)、CD3+、CD4+水平均低于对照组,CD8+水平、各项生存质量评分均高于对照组,差异有统计学意义(P<0.05);观察组口腔黏膜炎、吞咽疼痛发生率低于对照组,差异有统计学意义(P<0.05)。结论调强放疗联合奈达铂同步化疗可降低肿瘤标志物水平,增强免疫功能,改善生存质量,且不良反应轻。 展开更多
关键词 头颈部鳞状细胞癌 局部晚期 调强放疗 奈达铂 肿瘤标志物 生存情况
暂未订购 下载PDF
CIK免疫治疗联合TP方案化疗对食管癌生存质量的影响 认领 引用
16
作者 王孟蝶 祁宁宁 侯园 《锦州医科大学学报》 CAS 2025年第1期87-91,共5页
目的观察细胞因子诱导的杀伤细胞(cytokine induced killer,CIK)免疫治疗联合奈达铂+紫杉醇方案化疗对食管癌患者临床疗效及生存质量的影响。方法选取河南科技大学第一附属医院收治的66例食管癌患者,病例纳入时间为2020年1月至2022年1月... 目的观察细胞因子诱导的杀伤细胞(cytokine induced killer,CIK)免疫治疗联合奈达铂+紫杉醇方案化疗对食管癌患者临床疗效及生存质量的影响。方法选取河南科技大学第一附属医院收治的66例食管癌患者,病例纳入时间为2020年1月至2022年1月,随机均分为研究组(n=33)和对照组(n=33)。对照组给予奈达铂+紫杉醇方案化疗,在此基础上研究组加用CIK免疫治疗。比较两组临床疗效、治疗前后免疫指标、生存质量、毒副反应及随访24个月的生存情况。结果研究组客观缓解率(objective response rate,ORR)和疾病控制率(disease control rate,DCR)高于对照组(P<0.05);治疗后,研究组血清T淋巴细胞亚群CD3+、CD4+、CD4+/CD8+比值水平高于对照组(P<0.05);研究组卡氏功能状态(KPS)评分高于对照组(P<0.05);治疗期间,研究组骨髓抑制和肝肾功能损害的毒副反应总发生率低于对照组(P<0.05);随访结果,研究组12个月和24个月的生存率高于对照组(P<0.05)。结论CIK免疫治疗联合奈达铂+紫杉醇方案化疗可有效提高食管癌患者的临床疗效,改善机体免疫功能,提高生存质量,降低毒副反应,并一定程度上延长生存期。 展开更多
关键词 细胞因子诱导的杀伤细胞 细胞免疫 奈达铂 紫杉醇 食管癌 生存质量
暂未订购 下载PDF
加减八珍汤联合紫杉醇+奈达铂方案治疗中晚期宫颈癌的临床疗效及其对炎性细胞因子水平的影响 认领 引用
17
作者 赵俊哲 王永花 +1 位作者 万颜婕 丁鑫 《青海医药杂志》 CAS 2025年第10期1-5,共5页
目的:探讨加减八珍汤联合紫杉醇+奈达铂治疗中晚期宫颈癌患者的临床疗效及其对炎性细胞因子水平的影响。方法:以2022年9月—2023年9月我院收治的90例中晚期宫颈癌患者为观察对象,按照计算机表法分为对照组和研究组各45例。对照组予以常... 目的:探讨加减八珍汤联合紫杉醇+奈达铂治疗中晚期宫颈癌患者的临床疗效及其对炎性细胞因子水平的影响。方法:以2022年9月—2023年9月我院收治的90例中晚期宫颈癌患者为观察对象,按照计算机表法分为对照组和研究组各45例。对照组予以常规化疗,研究组予以加减八珍汤联合紫杉醇+奈达铂治疗,观察并比较两组患者治疗前后血清肿瘤标志物[鳞状上皮细胞癌相关抗原(SCC-Ag)、细胞角蛋白21-1(CYFRA21-1)]水平、炎性细胞因子[白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、白细胞介素-5(IL-5)、白细胞介素-10(IL-10)、干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)]水平和不良反应发生情况。结果:治疗后,研究组SCC-Ag水平(1.75±0.65)mg/L、CYFRA21-1水平(2.16±0.72)mg/L,均低于对照组(P<0.05);研究组IL-2水平(1355.45±150.86)ng/L、IFN-γ水平(698.54±80.56)ng/L、TNF-α水平(220.63±45.85)ng/L,均高于对照组(P<0.05);研究组IL-4水平(23.53±5.42)ng/L、IL-5水平(381.45±55.86)ng/L、IL-10水平(25.42±4.26)ng/L,均低于对照组(P<0.05);研究组不良反应发生率为6.66%,低于对照组(P<0.05)。结果:加减八珍汤联合紫杉醇+奈达铂化疗方案应用于中晚期宫颈癌患者中,能有效降低患者血清肿瘤标志物水平,改善炎性细胞因子水平,降低不良反应发生率,值得临床推广应用。 展开更多
关键词 中晚期宫颈癌 八珍汤 紫杉醇 奈达铂 炎性细胞因子 临床疗效
暂未订购 下载PDF
信迪利单抗联合紫杉醇、奈达铂治疗晚期非小细胞肺癌的效果观察 认领 引用 被引量：7
18
作者 宋和平 陈嘉捷 《实用癌症杂志》 2025年第2期227-229,共3页
目的 观察信迪利单抗联合紫杉醇、奈达铂治疗晚期非小细胞肺癌的疗效及安全性。方法 选取非小细胞肺癌晚期患者120例,简单随机法分为对照组(n=60)和观察组(n=60),对照组予以奈达铂(80 mg/m2)+紫杉醇(260 mg/m2)治疗,观察组予以奈... 目的 观察信迪利单抗联合紫杉醇、奈达铂治疗晚期非小细胞肺癌的疗效及安全性。方法 选取非小细胞肺癌晚期患者120例,简单随机法分为对照组(n=60)和观察组(n=60),对照组予以奈达铂(80 mg/m2)+紫杉醇(260 mg/m2)治疗,观察组予以奈达铂(80 mg/m2)+紫杉醇(260 mg/m2)+信迪利单抗(200 mg/m2)治疗,记录2组临床疗效、血清肿瘤标志物、免疫细胞水平、不良反应。结果 观察组ORR高于对照组(P0.05)。结论 信迪利单抗联合紫杉醇、奈达铂治疗晚期非小细胞肺癌,可有效提高疗效,其治疗作用可能与调节肿瘤标志物水平、免疫细胞水平有关,且不良反应可控。 展开更多
关键词 非小细胞肺癌 晚期 信迪利单抗 紫杉醇 奈达铂
暂未订购 下载PDF
奈达铂通过激活氧化应激和Caspase-9介导的线粒体凋亡抑制黑色素瘤细胞增殖、迁移及侵袭 认领 引用 被引量：1
19
作者 穆毅 宫玉龙 +1 位作者 邓凯 段钰泽 《陕西医学杂志》 CAS 2025年第11期1456-1462,共7页
目的:探讨奈达铂通过激活氧化应激和半胱氨酸依赖的天冬氨酸特异性蛋白酶-9(Caspase-9)介导的线粒体凋亡对黑色素瘤细胞的作用。方法:将黑色素瘤A375细胞随机分为对照组、奈达铂组、奈达铂+硫辛酸组、奈达铂+si-NC组和奈达铂+si-Caspas... 目的:探讨奈达铂通过激活氧化应激和半胱氨酸依赖的天冬氨酸特异性蛋白酶-9(Caspase-9)介导的线粒体凋亡对黑色素瘤细胞的作用。方法:将黑色素瘤A375细胞随机分为对照组、奈达铂组、奈达铂+硫辛酸组、奈达铂+si-NC组和奈达铂+si-Caspase-9组。对照组不进行任何药物处理;奈达铂组用10μmol/L奈达铂处理24 h;奈达铂+硫辛酸组用10μmol/L奈达铂和50μmol/L硫辛酸联合处理24 h;奈达铂+si-NC组加入10μmol/L奈达铂和100 nmol/L si-NC处理24 h;奈达铂+si-Caspase-9组加入10μmol/L奈达铂和100 nmol/L si-Caspase-9处理24 h。检测各组氧化应激指标[活性氧(ROS)、丙二醛(MDA)、超氧化物歧化酶(SOD)]、线粒体凋亡相关蛋白[Caspase-9、剪切型Caspase-3(Cleaved Caspase-3)、B细胞淋巴瘤-2(Bcl-2)、Bcl-2相关X蛋白(Bax)]、线粒体膜电位、ATP含量、细胞增殖活性、迁移率和侵袭率。结果:与对照组比较,奈达铂组ROS和MDA水平、Caspase-9和Cleaved Caspase-3蛋白表达水平及Bax/Bcl-2比值升高,SOD水平、线粒体膜电位增加率和正常率、ATP含量、细胞增殖活性、细胞迁移率、细胞侵袭率降低(均P<0.05)。与奈达铂组比较,奈达铂+硫辛酸组SOD水平、细胞增殖活性、细胞迁移率、细胞侵袭率升高,ROS和MDA水平降低(均P<0.05)。与奈达铂+si-NC组比较,奈达铂+si-Caspase-9组Caspase-9、Cleaved Caspase-3蛋白表达水平及Bax/Bcl-2比值降低,线粒体膜电位增加率和正常率、ATP含量、细胞增殖活性、细胞迁移率、细胞侵袭率升高(均P<0.05)。结论:奈达铂通过激活氧化应激和Caspase-9介导的线粒体凋亡抑制黑色素瘤细胞的增殖、迁移和侵袭。 展开更多
关键词 黑色素瘤 奈达铂 氧化应激 线粒体凋亡 半胱氨酸依赖的天冬氨酸特异性蛋白酶-9 增殖 迁移 侵袭
暂未订购 下载PDF
信迪利单抗联合白蛋白结合型紫杉醇与奈达铂治疗宫颈癌的效果 认领 引用 被引量：2
20
作者 李虹霖 赵莉 《中外医学研究》 2025年第12期41-44,共4页
目的:探析宫颈癌患者采用信迪利单抗联合白蛋白结合型紫杉醇、奈达铂治疗的临床效果。方法:选取2023年4月—2024年4月广州中医药大学金沙洲医院收治的82例宫颈癌患者作为研究对象,通过随机数表法分为试验组(n=41)和对照组(n=41)。对照... 目的:探析宫颈癌患者采用信迪利单抗联合白蛋白结合型紫杉醇、奈达铂治疗的临床效果。方法:选取2023年4月—2024年4月广州中医药大学金沙洲医院收治的82例宫颈癌患者作为研究对象,通过随机数表法分为试验组(n=41)和对照组(n=41)。对照组治疗方案为白蛋白结合型紫杉醇联合奈达铂,试验组治疗方案为信迪利单抗联合白蛋白结合型紫杉醇、奈达铂治疗。比较两组近期疗效、远期疗效、炎症因子及免疫指标水平、血清肿瘤标记物水平、不良反应发生率。结果:试验组疾病缓解率、疾病控制率较对照组更高,差异有统计学意义(P0.05)。结论:宫颈癌患者采用信迪利单抗联合白蛋白结合型紫杉醇、奈达铂治疗近期及远期疗效显著,可缓解炎症反应,调节免疫功能,降低血清肿瘤标记物水平,治疗安全性较高。 展开更多
关键词 信迪利单抗 白蛋白结合型紫杉醇 奈达铂 宫颈癌
暂未订购 下载PDF
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 2 … 42 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈